Long-term Efficacy and Safety of HMS5552 add-on to Metformin in T2DM Subjects

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 767 participants.

Also called NCT03141073

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 767 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03141073
Other papers using this trial's data
  • Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial Nature medicine, 2022-05 DOI, PubMed 35551292, PMC9117147 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03141073. Randomized; quadruple masking; primary purpose treatment. Start 2017-10-15 (actual); primary completion 2021-02-28 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Long-term Efficacy and Safety of HMS5552 add-on to Metformin in T2DM Subjects
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
HMS5552
Intervention (Drug)
Placebo
Lead sponsor
Hua Medicine Limited (class: industry)
Collaborator
Covance (class: industry)

Record details

Record id
cardio:ct-nct03141073
Content hash
457c19dec539597e3d66a14b5a2833a39ec47738efcadb9d02f40b329f1a0f61